AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01078168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: 30mg per day from Day 1 to Day 28
Study NCT01078168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01875731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
Study NCT01875731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: Strategy based on enforced guideline guided antibiotic use
Study NCT02400268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 days course of antibiotic treatment
Description: Standard antibiotic treatment approved for enterobacteraciae infections
Study NCT03330470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: participants will be subjected to 3 months supervised exercise intervention
Study NCT03330470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnosine supplementation
Description: participants will be instructed to take carnosine 2 times daily
Study NCT03330470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching
Description: participants will be subjected to 3 months supervised stretching program
Study NCT03330470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation with placebo
Description: participants will be instructed to take placebo 2 times daily
Study NCT03287427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TetMYB Vaccine
Description: Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
Study NCT03287427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: 3 weekly IV injections of 200mg commencing from Week 4.
Study NCT02217917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
Study NCT02217917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo administered as single dose subcutaneously with rHuPH20.
Study NCT02217917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
Study NCT02217917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
Study NCT02217917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: Transthoracic echocardiography
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: Exercise test
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: 24-hour Holter electrocardiogram
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: Contrast-enhanced magnetic resonance imaging
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: 123-iodine metaiodobenzylguanidine imaging
Study NCT01940081 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Study NCT01940081 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Study NCT01940081 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive electrophysiological study
Study NCT01940081 — intervention group
Intervention type: PROCEDURE
Intervention: Endomyocardial biopsy
Study NCT01940081 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative biopsy
Study NCT01940081 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative mapping and/or ablation
Study NCT02126839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: 90 mcg/actuation of the multidose dry powder inhaler (MDPI).
Study NCT02126839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
Study NCT02126839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAir HFA inhaler
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
Study NCT02126839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ProAir HFA inhaler
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
Study NCT00172042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Study NCT01471379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 50mg Milnacipran PO, BID, for 6 weeks.
Study NCT01471379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: 50mg Milnacipran PO, BID, for 6 weeks.
Study NCT01471379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Milnacipran, 100mg PO, BID, for six weeks
Study NCT01471379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Milnacipran, 50mg PO BID for 12 weeks
Study NCT01471379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
Study NCT05537077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
Study NCT00172042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Study NCT05537077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
Study NCT05537077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack therapy
Description: Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
Study NCT04444609 — intervention group
Intervention type: OTHER
Intervention: Blood tests sputum, nasal lavage and brushing
Description: Venesection, sputum nasal lavage and brushing if appropriate
Study NCT04863755 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH
Description: Patients receive DASH diet orientation and recommended to maintain their usual physical activity
Study NCT04863755 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASHPED
Description: Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
Study NCT01048723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Patients were instructed to take RAD001 in the morning, at the same time each day.
Study NCT03266991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
Study NCT03266991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Treatment with daily isoniazid in 6 months
Study NCT03266991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Treatment with daily isoniazid in 6 months
Study NCT01103609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral tablet od on Day 4
Study NCT01103609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Oral tablet od on Day 4
Study NCT01103609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet bd, stepwise increased
Study NCT01103609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd, stepwise increased
Study NCT02213393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enriched products
Description: The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
Study NCT02213393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual menu
Description: The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
Study NCT03630809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
Study NCT03630809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
Study NCT03145168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Target Mean Arterial Pressure
Description: High target group (80-85 mm of Hg).
Study NCT03145168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Target Mean Arterial Pressure
Description: Low target MAP group (60-65mm Hg).
Study NCT03760146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC
Study NCT03760146 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study NCT02400268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days course of antibiotic treatment
Description: Standard antibiotic treatment approved for enterobacteraciae infections
Study NCT02422550 — intervention group
Intervention type: DEVICE
Intervention: MRI or CT
Description: Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
Study NCT00202267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Four-layer Bandage (Elastomeric)
Description: Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
Study NCT00202267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-stretch Bandage (Non-elastomeric)
Description: These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
Study NCT02757651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide
Study NCT03760146 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study NCT03760146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study NCT02874742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
Study NCT02874742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
Study NCT02874742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
Study NCT02874742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
Study NCT03930446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
Study NCT03930446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
Study NCT04252755 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EEG Neurofeedback
Description: Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
Study NCT03295708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil capsule
Description: N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
Study NCT03295708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil capsule
Description: placebo capsule
Study NCT00665977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thermosmart & placebo
Description: a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
Study NCT00665977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Device & Nasacort
Description: Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
Study NCT00665977 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Arm
Description: To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.
Study NCT01793727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope
Study NCT01359254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Study NCT01359254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is given through the vein daily for 5 days.
Study NCT01359254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin (ATG)
Description: ATG is given every other day for 4 days.
Study NCT01359254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is given daily for 4 days.
Study NCT01359254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI is given twice on the last day.
Study NCT00265512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Case Monitoring
Description: Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
Study NCT00265512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuing Care as Usual
Description: Continuing Care as Usual will include standard group outpatient SUD treatment.
Study NCT04390594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant
Study NCT03637803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
Study NCT03637803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Description: Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
Study NCT02338765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Physical Activity
Study NCT02338765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Physical Activity
Study NCT02338765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy-partnered exercise
Study NCT01828892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
Study NCT01828892 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endoscopy exploration
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.